Carmine Therapeutics to Present at Biotech Showcase™ 2023

Presenting Tuesday, January 10, 2023 10 AM PST

Franciscan-C, Level Ballroom

Key Takeaways

Carmine’s REGENT® gene therapy delivery platform offers several competitive advantages over both AAV and LNP, including safety, tolerability, expression, durability, and applicability.
The ability to redose Carmine’s RBCEVs, as well as the flexibility to include multiple payloads beyond the capacity of AAV, while targeting many tropisms, opens the door to the use of gene therapy to target diseases not previously addressable by first- and second-generation approaches.
Carmine is led by industry veterans with decades of experience in the gene and cell therapy market, along with a world renowned scientific advisory and board of directors.

Cambridge, MA/January 5, 2023 – Carmine Therapeutics, today announced that it is presenting at Biotech Showcase™ 2023. This year, registered attendees can view Carmine's presentation live, and also access a recorded version beginning November 29th – SIX weeks prior to the actual event. With 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.

Don Haut, PhD, CEO, will be presenting Carmine Therapeutics at Biotech Showcase.

Date: Tuesday, January 10th, 2023

Time: 10:00am PT

Track: Franciscan C

"Over the past year, we have shown that our platform has enormous potential, delivering DNA payloads of over 30kb, and offering high-amplitude and long-duration transgene expression in a re-dosable and non-inflammatory format. Our first programs in Stargardt disease and Cystic Fibrosis are progressing well towards IND next year. So, I am thrilled to have the opportunity to share Carmine’s data and story at the Biotech Showcase," said Don Haut, PhD, CEO of Carmine Therapeutics.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.

“We are delighted that Carmine Therapeutics will be joining us in San Francisco and presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”

About Carmine Therapeutics

Carmine Therapeutics was founded in 2019 by EVX Ventures, Professor Harvey Lodish (Whitehead, MIT) and Singaporean Professors Minh Le and Jiahai Shi. Professor Lodish, who was a founding member of several successful biotech companies that include Genzyme, Arris (now Axys) Pharmaceuticals, Millennium Pharmaceuticals and Rubius Therapeutics, is also Chair of the Scientific Advisory Board of Carmine. Headquartered in Cambridge, MA with a research presence in Singapore, Carmine is pioneering next generation gene therapy based on red blood cell extracellular vesicles.

About Biotech Showcase
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 15th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

Key Takeaways

Carmine’s REGENT® gene therapy delivery platform offers several competitive advantages over both AAV and LNP, including safety, tolerability, expression, durability, and applicability.
The ability to redose Carmine’s RBCEVs, as well as the flexibility to include multiple payloads beyond the capacity of AAV, while targeting many tropisms, opens the door to the use of gene therapy to target diseases not previously addressable by first- and second-generation approaches.
Carmine is led by industry veterans with decades of experience in the gene and cell therapy market, along with a world renowned scientific advisory and board of directors.

Media Gallery

Quotes

“

Over the past year, we have shown that our platform has enormous potential, delivering DNA payloads of over 30kb, and offering high-amplitude and l...

Don Haut, Ph.D. — CEO

Related Bios

Don Haut, Ph.D.

CEO

Dr. Haut was Chief Business Officer of AskBio, where he led the firm’s business development activities and spearheaded AskBio’s $4 billion acquisition by Bayer AG. In a career spanning academic science, consulting, sales management, and business development, he has completed transactions exceeding $8 billion and been instrumental in multiple product launches. He has also served on the boards of several healthcare companies, including firms involved in joint replacement and repair.

Originally trained as a molecular biologist before joining McKinsey, Dr. Haut has since held senior business roles at 3M Company, Smith & Nephew, and The Medicines Company. More recently, he was Chief Business Officer of Histogenics and Sherlock Biosciences. He earned his PhD in Molecular Biology from the Medical School at the University of Missouri-Columbia and an MBA from Washington University’s Olin School of Business.

View Full Bio>>

John Robblee, Ph.D

Vice President, CMC

Dr. Robblee brings over 15 years of development experience to the Chemistry, Manufacturing, and Controls (CMC) function at Carmine. At the exosome therapeutics company Codiak BioSciences, he led the Analytical Development team and played a leading Regulatory and CMC role in the successful IND/IMPD submissions of their first clinical products exoSTING and exoIL-12.

Before leading the Analytical Development team at the non-viral gene therapy company Generation Bio, he spent over a decade at Momenta Pharmaceuticals in the Analytical Research, Analytical Development, and CMC Regulatory groups on the analytical and regulatory framework for most of their biosimilar products, including biosimilar versions of Humira®, Orencia®, and Eylea®.

Dr. Robblee received his Ph.D. from the University of California, Berkeley in biophysical chemistry, and completed his postdoctoral training in the biochemistry department of the Massachusetts Institute of Technology.

View Full Bio>>

Qin Yu, Ph.D.

Vice President, Discovery

Qin has over 15 years of drug discovery and development experience. She previously was the Senior Director of Viral Therapeutics at Ascidian Therapeutics and the Director of Platform Technology at Rubius Therapeutics.

Qin brings her extensive R&D experience with gene therapy vectors and red blood cell-based therapy to Carmine. She most recently served as the Senior Director at Ascidian Therapeutics, leading the in vitro and in vivo Proof of Concept research for a novel gene therapy platform.

Prior to that Qin was the Director of Platform Technology at Rubius Therapeutics, building the team from the ground up and leading the Red Cell Therapeutics platform and early programs to successful IND submissions.

Qin’s industry career started on leading antiviral drug discovery teams and projects at a biotech and later at Novartis and AstraZeneca. She received her Ph.D. in Microbiology from the University of Alabama at Birmingham. Her postdoctoral training was completed at the Salk Institute for Biological Studies.

View Full Bio>>

Tenzin Gocha, Ph.D.

Director, Scientific & Business Operations

Tenzin obtained his Ph.D. in Molecular Pharmacology from New York University Medical Center. During his Ph.D., he studied the effect of perturbation of cell signaling pathways in the context of cancer and embryonic stem cells. Tenzin has co-authored 5 publications and one book chapter in the fields of RNAi and small molecule and small-biologic screening.

After his Ph.D., Tenzin did a short postdoctoral stint at the Genome Institute of Singapore, in collaboration with an industrial partner on discovering small-biologics against immunomodulating receptors. Tenzin is a Fulbright Scholar and recipient of several graduate fellowships.

View Full Bio>>

Ozan Alkan, Ph.D.

Vice President, Molecular Biology

Dr. Alkan's passion and interest in gene therapy started 20 years ago while working in Germany's first gene therapy group and trial. His Ph.D. studies focusing on non-and viral gene therapy vectors were a close collaboration between the University of Freiburg in Germany and M.I.T. He was a visiting student in Philip Leboulch's lab, the scientific founder of the company Bluebird. He continued his training as a PostDoc in Helen Blau's lab at Stanford University in the field of Stem Cell Biology.

His subsequent career steps brought him to the Broad Institute of Harvard and M.I.T. as a group leader, followed by a industry-based group leader position in a mid-size Cambridge-based biotech company Merrimack Pharmaceuticals. There, he extended his knowledge in virology and alternative delivery moieties, using liposomal nanoparticles (LNP) to deliver nucleic acids, such as plasmid and small interfering RNAs.

His interest and dedication towards the optimization of non-viral gene therapy platforms and technologies were further enhanced by joining a start-up in Cambridge where he helped building re-dosable and titratable gene therapy platforms based on linear close-end DNA species. Shortly before joining Carmine, Ozan focused on establishing and developing RNA-based LNP delivery platforms and reprogramming T-Cells invivo at Tidal Therapeutics.

View Full Bio>>

Contacts

Chelli Miller

chelli@contentcarnivores.com

2199216823